| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
In the present study, to make an attempt to confer a tumor cell-selectivity to M-β-CyD, we newly synthesized folate-appended M-β-CyD (FA1-M-β-CyD), and evaluated the potentials as its novel tumor-selective carrier for antitumor drugs. FA1-M-β-CyD showed potent antitumoreffects in FR-expressing tumor cells in vitro and in vivo. Furthermore, Doxorubicin/FA1-M-β-CyD complex showed the potent antitumor activity after single intravenous injection to tumor-bearing mice, compared to doxorubicin alone and DOX/M-β-CyD complex. In conclusion, the present study demonstrated the potentials of FA1-M-β-CyD as a novel tumor-selective carrier for antitumor drugs.
|
